Role of CYP3A enzymes in the biotransformation of triazolam in rat liver

Xenobiotica

Volumn 34, Issue 5, 2004, Pages 463-471

  Warrington, J S ^a   Greenblatt, D J ^a   Von Moltke, L L ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYTOCHROME P450; CYTOCHROME P450 3A; CYTOCHROME P450 INHIBITOR; ENZYME ANTIBODY; HYDROXIDE; KETOCONAZOLE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TRIAZOLAM;

ADULT; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CLEARANCE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG TRANSFORMATION; ENZYME ANALYSIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIVER MICROSOME; MALE; METABOLISM; MICHAELIS MENTEN KINETICS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT;

ADULT; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CYTOCHROME P-450 CYP3A; ENZYME INHIBITORS; HUMANS; HYDROXYLATION; ISOENZYMES; KETOCONAZOLE; KINETICS; MALE; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; RATS; RATS, INBRED F344; RECEPTORS, GABA-A; RECOMBINANT PROTEINS; TRIAZOLAM;

ANIMALIA; STAPHYLOCOCCUS PHAGE 3A;

EID: 3142552532     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250410001691299     Document Type: Article

References (21)

1. ABURAWI, S. M., AHMED, S. S., ELHWUEGI, A. S., SAAD, S. F. and ATTIA, A. S., 2001, Brain glycine levels in triazolam-treated albino rats. Journal of Neural Transmission, 108, 527-539.
2. GAUDREAULT, J., VARIN, F. and POLLACK, G. M., 1996, Anticonvulsant pharmacodynamics and disposition of triazolam in rats. Journal of Pharmaceutical Science, 85, 999-1004.
3. GREENBLATT, D. J., WRIGHT, C. E., VON MOLTKE, L. L., HARMATZ, J. S., EHRENBERG, B. L., HARREL, L. M., CORBETT, K., COUNIHAN, M., TOBIAS, S. and SHADER, R. I., 1998, Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. Clinical Pharmacology and Therapy, 64, 237-247.
4. GRIEBEL, G., PERRAULT, G. and SANGER, D. J., 1998, Limited anxiolytic-like effects of non-benzodiazepine hypnotics in rodents. Journal of Psychopharmacology, 12, 356-365.
5. GUENGERICH, P., DANNAN, G. A., WRIGHT, S. T., MARTIN, M. V. and KAMINSKY, L. S., 1982, Purification and characterization of liver microsomal cytochromes P-450: electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated vyith phenobarbital or β-naphthoflavone. Biochemistry, 21, 6019-6030.
6. IMAOKA, S., TERANO, Y. and FUNAE, Y., 1990, Changes in the amount of cytochrome P450s in rat hepatic microsomes with starvation. Archives of Biochemistry and Biophysics, 278, 168-178.
7. KOBAYASHI, K., URASHIMA, K., SHIMADA, N. and CHIBA, K., 2002, Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat. Biochemical Pharmacology, 63, 889-896.
8. KOTEGAWA, T., LAURIJSSENS, B. E., VON MOLTKE, L. L., COTREAU, M. M., PERLOFF, M. D., VENKATAKRISHNAN, K., WARRINGTON, J. S., GRANDA, B. W., HARMATZ, J. S. and GREENBLATT, D. J., 2002, In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. Journal of Pharmacology and Experimental Therapeutics, 302, 1228-1237.
9. KRONBACH, T., MATHYS, D., UMENO, M., GONZALEZ, F. J. and MEYER, U. A., 1989, Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Molecular Pharmacology, 36, 89-96.
10. LAKE, B. G., 1987, Preparation and characterization of microsomal fraction for studies on xenobiotic metabolism. In K. Snell and B. Mullock (eds), Biochemical Toxicology: A Practical Approach (Oxford: IRL Press), pp. 183-215.
11. LAURIJSSENS, B. E. and GREENBLATT D. J., 2002, Effect of 7-day exposure to midazolam on electroencephalogram pharmacodynamics in rats: a model to study multiple pharmacokinetic-pharmacodynamic relationships in individual animals. Journal of Pharmacy and Pharmacology, 54, 77-86.
12. NAKASHIMA, K., YAMAMOTO, K., AL-DIRBASHI, O. Y. and NAKASHIMA, M. N., 2002, Disposition of triazolam in the rat by brain microdialysis and semi-micro column high-performance liquid chromatography with UV absorbance detection. Biomedical Chromatography, 16, 219-223.
13. PERLOFF, M. D., VON MOLTKE L. L. and GREENBLATT, D. J., 2003, Differential metabolism of midazolam in mouse liver and intestine microsomes: a comparison of cytochrome P450 activity and expression. Xenobiotica, 33, 365-377.
14. PERLOFF, M. D., VON MOLTKE, L. L., COURT, M. H., KOTEGAWA, T., SHADER, R. I. and GREENBLATT, D. J., 2000, Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. Journal of Pharmacology and Experimental Therapeutics, 292, 618-628.
15. STRESSER, D. M., BROUDY, M. I., Ho, T., CARGILL, C. E., BLANCHARD, A. P., RAMAN SHARMA, DANDENEAU, A. A., GOODWIN, J. J., TURNER, S. D., ERVE, J. C. L., PATTEN, C. J., DEHAL, S. S. and CRESPI, C. L., 2004, Highly selective inhibition of human CYP3A in vitro by azamulin and evidence that inhibition is irreversible. Drug Metabolism and Disposition, 32, 105-112.
16. VENKATAKRISHNAN, K., VON MOLTKE L. L. and GREENBLATT D. J., 2000, Effects of the antifungal agents on oxidative drug metabolism in humans: clinical relevance. Clinical Pharmacokinetics, 38, 111-180.
17. VON MOLTKE, L. L., GREENBLATT, D. J., GRANDA, B. W., GIANCARLO, G. M., DUAN, S. X., DAILY, J. P., HARMATZ, J. S. and SHADER, R. I., 2001, Inhibition of human cytochrome P450 isoforms by non-nucleoside reverse transcriptase inhibitors. Journal of Clinical Pharmacology, 41, 85-91.
18. VON MOLTKE, L. L., GREENBLATT, D. J., HARMATZ, J. S., DUAN, S. X., HARREL, L. M., COTREAU-BIBBO, M. M., PRITCHARD, G. A., WRIGHT, C. E. and SHADER, R. I., 1996, Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. Journal of Pharmacology and Experimental Therapeutics, 276, 370-379.
19. VOORMAN, R. L., MAIO, S. M., PAYNE, N. A., ZHAO, Z., KOEPLINGER, K. A. and WANG, X., 1998, Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A. Journal of Pharmacology and Experimental Therapeutics, 287, 381-388.
20. WARRINGTON, J. S., POKU, J. W., VON MOLTKE, L. L., SHADER, R. I., HARMATZ, J. S. and GREENBLATT, D. J., 2000, Effects of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 292, 1024-1031.
21. WARRINGTON, J. S., VON MOLTKE, L. L., SHADER, R. I. and GREENBLATT, D. J., 2002, In vitro biotransformation of sildenafil (Viagra) in the male rat: the role of CYP2C11. Drug Metabolism and Disposition, 30, 655-657.